Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: human monoclonal antibodies - Abgenix/Protana

Drug Profile

Research programme: human monoclonal antibodies - Abgenix/Protana

Alternative Names: Human monoclonal antibodies research programme - Abgenix/Protana

Latest Information Update: 14 Mar 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abgenix; Protana
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 31 Dec 2004 Discontinued - Preclinical for Undefined in Canada (unspecified route)
  • 31 Dec 2004 Discontinued - Preclinical for Undefined in USA (unspecified route)
  • 18 Aug 2004 MDS Proteomics is now called Protana
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top